Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Cycloserine in Autism
NCT00198120Phase 3Completed
- Sponsor
- Indiana University
- Start
- Feb 2004
- Primary completion
- Sep 2007
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing D-cycloserine with Placebo (2 arms). Primary endpoints: Clinical Global Impressions Global Improvement at 8 weeks and Aberrant Behavior Checklist Lethargy Subscale at 8 weeks. Started Feb 2004; status: completed.
02
Drugs
d-cycloserine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00198120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198120.